Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $41

Benzinga · 10/09 17:04
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $23 to $41.